Related Experiment Video
Updated: Feb 14, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
A secondary RET mutation in the activation loop conferring resistance to vandetanib
Takashi Nakaoku1, Takashi Kohno2,3, Mitsugu Araki4,5
1Division of Genome Biology, National Cancer Center Research Institute, 5-1-1, Tsukiji, Chuo-ku, Tokyo, 1040045, Japan.
Abstract:
Resistance to vandetanib, a type I RET kinase inhibitor, developed in a patient with metastatic lung adenocarcinoma harboring a CCDC6-RET fusion that initially exhibited a response to treatment. The resistant tumor acquired a secondary mutation resulting in a serine-to-phenylalanine substitution at codon 904 in the activation loop of the RET kinase domain. The S904F mutation confers resistance to vandetanib by increasing the ATP affinity and autophosphorylation activity of RET kinase. A reduced interaction with the drug is also observed in vitro for the S904F mutant by thermal shift assay. A crystal structure of the S904F mutant reveals a small hydrophobic core around F904 likely to enhance basal kinase activity by stabilizing an active conformer. Our findings indicate that missense mutations in the activation loop of the kinase domain are able to increase kinase activity and confer drug resistance through allosteric effects.
Insights
A patient with lung adenocarcinoma developed resistance to vandetanib due to a RET kinase mutation. This S904F mutation increases kinase activity, leading to drug resistance via allosteric effects.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- Vandetanib is a type I RET kinase inhibitor used for metastatic lung adenocarcinoma.
- CCDC6-RET fusions are common drivers in certain lung cancers, initially responsive to RET inhibitors.
Observation:
- A patient with a CCDC6-RET fusion-positive tumor developed acquired resistance to vandetanib.
- The resistant tumor acquired a secondary RET kinase domain mutation, S904F (serine-to-phenylalanine at codon 904).
Findings:
- The S904F mutation increases RET kinase's ATP affinity and autophosphorylation activity.
- In vitro thermal shift assays showed reduced interaction between vandetanib and the S904F mutant.
- Crystal structure of the S904F mutant revealed a stabilized active conformer, enhancing basal kinase activity.
Implications:
- Missense mutations in the RET kinase activation loop can confer drug resistance.
- These mutations increase kinase activity through allosteric effects, impacting therapeutic strategies.
- Understanding resistance mechanisms is crucial for developing next-generation RET inhibitors.
Related Concept Videos
Secondary Active Transport
Secondary Active Transport
Mutations
Mutations
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...
Viral Mutations
Primary and Secondary Growth in Roots and Shoots

